Kaori Shinjo

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

Kensuke Naito, Akihiro Takeshita, Kohichiro Shigeno et al. · Leukemia · 2000 · 152 citations

Hematological Malignancy, Cytocidal Effect, P-glycoprotein-expressing Sublines +10

Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies

Kazuyuki Shigeno, Kensuke Naito, Miki Kobayashi et al. · International Journal of Hematology · 2005 · 111 citations

Hematological Malignancy, Oncology, Hematology +6

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

Hirotaka Matsui, Akihiro Takeshita, Kensuke Naito et al. · Leukemia · 2002 · 104 citations

Hematological Malignancy, Gemtuzumab Ozogamicin, Health Sciences +10

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring

Kazunori Ohnishi, Hitoshi Yoshida, Kohichiro Shigeno et al. · Leukemia · 2002 · 99 citations

Careful Electrocardiogram Monitoring, Hematology, Refractory Japanese Patients +2

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

Shinya Fujisawa, Ryuzo Ohno, Kazuyuki Shigeno et al. · Cancer Chemotherapy and Pharmacology · 2006 · 64 citations · Full text

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +8